<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600755</url>
  </required_header>
  <id_info>
    <org_study_id>09-025</org_study_id>
    <nct_id>NCT01600755</nct_id>
  </id_info>
  <brief_title>Autologous Cell Therapy for Treatment of Fecal Incontinence</brief_title>
  <official_title>A Prospective Nonrandomized Study of Autologous Muscle Derived Cell (AMDC) Transplantation for Treatment of Fecal Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook MyoSite</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <brief_summary>
    <textblock>
      The aim of this clinical study is to investigate the safety and feasibility of Autologous
      Muscle Derived Cells (AMDC; a preparation of a patient's own cells) injection into the anal
      sphincter for treatment of patients with fecal incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of incontinent episodes</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence score</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphincter pressure</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>AMDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMDC</intervention_name>
    <description>Cell Treatment</description>
    <arm_group_label>AMDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary symptoms of fecal incontinence, as confirmed by patient medical history and
             physical examination

          -  Wexner score â‰¥ 9

          -  Failed conservative treatment

        Exclusion Criteria:

          -  Gracilis sling repair or insertion of an artificial sphincter

          -  Inflammatory Bowel Disease

          -  Significant rectocele or rectal prolapse

          -  History of radiation treatment to the anal sphincter or adjacent structures

          -  Less than 18 years of age

          -  Pregnant, breastfeeding, or plans to become pregnant during the course of the study

          -  Neuromuscular disorder

          -  History of neoplasia within 5 years prior to enrollment, except for basal cell
             carcinoma, or is receiving or planning to receive anti-cancer medications

          -  Known bleeding diathesis or uncorrected coagulopathy

          -  Medical condition that would preclude treatment due to contraindications and/or
             warnings of concomitant medications or listed in the experimental product labeling

          -  Participating in another investigational drug or device study

          -  Unable or unwilling to provide informed consent

          -  Unable or unwilling to commit to the follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yahira Baez-Santos, PhD</last_name>
    <phone>800-356-9208</phone>
    <email>yahira.baez-santos@cookmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoj J. Raval, MD</last_name>
      <phone>604-806-8711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Knowles, Prof</last_name>
      <phone>+44(0)2078828757</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>Autologous Cell Transplantation</keyword>
  <keyword>Muscle-derived Cell</keyword>
  <keyword>Anal Incontinence</keyword>
  <keyword>Rectal Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Urinary Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

